Efficacy of an irreversible BTK inhibitor, Ibrutinib on allergen reactivity in patients suffering from B-cell malignancies

Trial Profile

Efficacy of an irreversible BTK inhibitor, Ibrutinib on allergen reactivity in patients suffering from B-cell malignancies

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2017 New trial record
    • 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top